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Background: Cincinnati Children’s Hospital Medical Center (CCHMC) has built the initial Natural Language
Processing (NLP) component to extract medications with their corresponding medical conditions (Indications,
Contraindications, Overdosage, and Adverse Reactions) as triples of medication-related information ([(1) drug
name]-[(2) medical condition]-[(3) LOINC section header]) for an intelligent database system, in order to improve
patient safety and the quality of health care. The Food and Drug Administration’s (FDA) drug labels are used to
demonstrate the feasibility of building the triples as an intelligent database system task.
Methods: This paper discusses a hybrid NLP system, called AutoMCExtractor, to collect medical conditions
(including disease/disorder and sign/symptom) from drug labels published by the FDA. Altogether, 6,611 medical
conditions in a manually-annotated gold standard were used for the system evaluation. The pre-processing step
extracted the plain text from XML file and detected eight related LOINC sections (e.g. Adverse Reactions, Warnings
and Precautions) for medical condition extraction. Conditional Random Fields (CRF) classifiers, trained on token,
linguistic, and semantic features, were then used for medical condition extraction. Lastly, dictionary-based post-
processing corrected boundary-detection errors of the CRF step. We evaluated the AutoMCExtractor on manually-
annotated FDA drug labels and report the results on both token and span levels.
Results: Precision, recall, and F-measure were 0.90, 0.81, and 0.85, respectively, for the span level exact match; for
the token-level evaluation, precision, recall, and F-measure were 0.92, 0.73, and 0.82, respectively.
Conclusions: The results demonstrate that (1) medical conditions can be extracted from FDA drug labels with high
performance; and (2) it is feasible to develop a framework for an intelligent database system.
Keywords: Medical condition, Disease and disorders, Sign and symptoms, cTAKES, NLP, Natural language
processing, IE, Information extraction, CRF, Conditional random fields, FDA drug labelsBackground
Every year, more than 2 million patients suffer serious Ad-
verse Drug Reactions (ADRs) in the US; of those, 100,000
reactions are fatal [1]. Due to this fact, the majority of pre-
vious work on detecting healthcare-related adverse events
has focused on identifying ADRs. ADRs have been ranked
among the top four causes of death in the US [2]. Cincin-
nati Children’s Hospital Medical Center (CCHMC) has
over 1 million patient-physician encounters a year. To
scale ADR detection to an encounter-volume this high,
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reproduction in any medium, provided the orproject and has implemented a trigger-tool based ap-
proach for a selected set of drugs [3]. In the case of
trigger-tools, an algorithm monitors the electronic patient
records for a drug-specific trigger (e.g. administration of
Naloxone to counter opiate overdose) and alerts hospital
management for potential ADRs. We describe a use-case
for developing an intelligent ADR database system by
extracting medications and their corresponding medical
conditions from FDA drug labels. It would be optimal to
extend the automated trigger-tool methodology to an
all-inclusive set of drugs; however, current trigger-tool
methodology requires manual database development for
the triggers. In other words, a human user needs to enter
ADR signs and symptoms into a database that serves as
the underlying data set to scan the EHR content for ADR
triggers.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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be self-sustaining and stay current with little or no hu-
man intervention. Our aim in this paper is to present
the results of building the first NLP-based component of
a proposed intelligent database system. This intelligent
database system could gather information from multiple
publicly-available sources, while continuously updating
itself after the initial setup. FDA drug labels could serve
as one of the main sources for candidate ADR data.
Additionally, Adverse Event Reporting System (AERS)
[4], full-text journal articles, and data with statistical
associations between drugs and signs and symptoms
collected from the EHR itself can also be resources. The
FDA publishes drug labels for most over-the-counter
(OTC) and prescription (Rx) drugs (37,907 drugs
altogether, as of 11/05/2012). As the FDA states on its
web site, “FDA-approved drug labels contain a wealth of
information about ADRs from clinical trials and post-
marketing surveillance. The information included in the
labels is agreed upon by regulatory, industry, and con-
sulting experts who have incorporated their contributions
over decades, reflecting the best thinking at the time.
Thus, the drug labelling implicitly balances the informa-
tion of causality, incidence, and severity based on 1) data
from controlled trials, 2) published literature reports,
and 3) spontaneous reports to AERS (adverse event
reporting systems)” [5].
Although as Boyce et al. have pointed out [6], drug
labels are not a perfect source of medication-related
medical information, there is nonetheless a wealth of in-
formation in the labels that represents important know-
ledge with strong implications for patient safety and the
quality of health care. Chen et al. applied FDA-drug
labels for detecting drugs that can induce liver injury [7].
Murphy et al. also stated, “The information included in
the labelling is the ‘true scoop’ and… the closest one can
get to the truth regarding the scientific information
known about a drug. The information contained in the
package insert or product information is the result of
careful and extensive analyses performed by the company
and then the FDA, using source data” [8]. In this paper,
as a use case for building an intelligent database, we
present our approach to “unearthing” the information
buried in the FDA label’s narrative text using natural
language processing (NLP) methodology. We also test
two hypotheses: that medical conditions can be extrac-
ted from FDA drug labels using scalable NLP methods,
and that the open source clinical Text Analysis and
Knowledge Extraction System (cTAKES) can be used for
textual genres other than clinical texts.
At the current time, the most common method of
ADR surveillance, within most healthcare organizations,
is largely a manual effort. Manual chart review tech-
niques require experts (e.g. physicians and nurses) toread the clinical notes of patients to parse out pertinent
safety information. This is time-consuming [9]. More-
over, as such chart review methods do not scale well to
large bodies of data, institutions usually utilize sampling
methods (i.e., randomly choosing portions of records)
for ADR detection. Phansalkar et al. found that pharma-
cists detected higher rates of adverse drug events than
non-pharmacists [10]. The chart review approach not
only requires the experts to have comprehensive know-
ledge of the administered medications and their associ-
ated indications, contraindications, and ADRs, but also
demands that the human reviewer be intimately familiar
with all details of the patients in order to be able to
judge if a new diagnosis, sign, or symptom recorded in
the notes is a potential ADR signal. The FDA previously
developed the Coding Symbols for Thesaurus of Adverse
Reaction Terms (COSTART) [11], which was used for
coding, filing, and retrieving post-marketing adverse
drugs and biologic experience reports. COSTART was
then superseded by the Medical Dictionary for Regula-
tory Activities (MedDRA) Terminology [12]. MedDRA
is endorsed by international organizations and is used
in multiple countries for safety reporting from pre-
marketing to post-marketing activities, as well as
medication-related data entry, retrieval, evaluation, and
presentation. These two systems are usually used for
medication coding, but do not provide methods for
automatically extracting medical conditions.
Some subsequent work used these dictionaries for fur-
ther medical condition extraction. He et al. proposed the
Adverse Event Ontology (AEO) to represent adverse
events [13]. However, AEO only covers 484 representa-
tion units, whereas MedDRA comprises 70,177 lowest-
level terms in version 15.0. In addition to MedDRA,
SNOMED CT was also successfully used to code terms
as potential ADRs. Alecu et al. demonstrated that
SNOMED CT codes, with cross-mapping by UMLS, can
be successfully translated into the MedDRA schema.
SNOMED CT has the advantage that it is fine-grained,
with detailed definitions of terms [14], so it is included
in our FDA label extraction results. The ADESSA sys-
tem, a real-time decision support service for detecting
or monitoring adverse drug events, uses a regular ex-
pression and dictionary-based method to extract ADRs
[15,16]. This system shows the viability of mining FDA
labels to discover ADR terms; it relies on MedDRA as a
dictionary to extract terms that represent ADRs in the
drug labels. Although the developers of ADESSA
reported good performance, the details of the regular-
expression algorithm and the evaluation are not pro-
vided. Moreover, even if the regular-expression-based
method has been found to be useful for a variety of
tasks, the limitation of this method is that if the ADR
terms are not recorded in the dictionary, then the
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variability will limit the usefulness of this method. Al-
though cTAKES has an ADR detection module [17], we
did not use it because the module was custom developed
for the text of clinical notes and not FDA labels, whose
texts are quite different. Moreover, we expected to collect
indications, contraindications and overdosage, as well,
which are not extracted as ADRs by the cTAKES system.
A machine learning algorithm with contextual features
has a chance to discover terms missed by dictionary-
based methods. Bisgin et al. successfully implemented
an unsupervised machine learning technique, Latent
Dirichlet Allocation (LDA), for topic modelling on FDA
labels [18]. They demonstrated how topic modelling via
unsupervised techniques could contribute to drug safety.
However, this kind of unsupervised learning method can
only detect the topics, not the entities. Semi-supervised
learning methods have been applied in named entity
detection. For example, Li et al. used a bootstrapping
method to detect named entities of locations and prod-
ucts in an industry corpus [19]. Although this method
can achieve high precision, recall is low, especially when
the size of sample seeds is small. Supervised learning
methods reported the highest overall performance.
Aramaki et al. used a supervised learning method to ex-
tract adverse drug events from Japanese clinical records.
Extracting drugs and symptoms from Japanese clinical
notes is quite different from disease/disorders and sign/
symptoms extraction from English drug labels, especially
concerning the features for supervised learning [20]. We
decided on a supervised method to serve as the core of
our hybrid system in light of the requirement of high
performance for information extraction tasks in the
healthcare domain.
In this work, we present a hybrid method used for
building the NLP component of an intelligent database
system. In this first step, we are focusing only on FDA
labels as the source of information. From the FDA
labels, the system collects triples of information: [(1)
drug name]-[(2) medical condition]-[(3) LOINC section
header]. Table 1 provides examples of triples that areTable 1 Excerpt of a drug label (Urea) annotated for three se
three triples
INDICATIONS AND USAGE: For debridement and
promotion of normal healing of hyperkeratotic surface lesions,
particularly where healing is retarded by local infection,
necrotic tissue, fibrinous or prurient debris or eschar.
Urea is useful for the treatment of hyperkeratotic conditions
such as dry, rough skin, dermatitis, psoriasis, xerosis, ichthyosis,
eczema, keratosis, keratoderma, corns and calluses.
ADVERSE REACTIONS: Transient stinging, burning,
itching or irritation may occur and normally disappear
on discontinuing the medication.
*The drug names and LOINC Sections are added to the triples via rules that utilize tcollected. This database will serve as one component of
the hospital’s ADR detection pipeline. The hybrid
method uses a supervised machine-learning algorithm –
Conditional Random Fields (CRF) – coupled with
handcrafted rules to collect the triples from the FDA drug
labels’ narrative texts. The information includes data about
medications and their corresponding medical conditions,
such as indications, contraindications, and adverse reac-
tions (manifested as disease/disorders and sign/symp-
toms). The reported work is a substantial step toward




The corpus is composed of 96,824 tokens or 52 FDA la-
bels randomly selected from 37,907 FDA drug labels
(accessed by 11/05/2012 on the DailyMed website) in-
cluding 18,999 Rx drugs and 19,072 OTC drugs [21]. It
covers three broad categories: OTC drugs (noted as
OTC), Rx drugs from the top 200 drugs in sales from
2010 according to drugs.com [22] (noted as Rx_Top200),
and other Rx drugs not part of the top 200 drugs in sales
(noted as Rx_Other). Table 2 lists the names and corre-
sponding National Drug Codes (NDCs) of five selected
drug labels from each category. The research is exempt
from human subjects research regulations. Conse-
quently, IRB approval was not necessary.
The original drug labels are in XML format. We
extracted the plain text version from the XML files.
Although the FDA drug labels include 80 different Lo-
gical Observation Identifiers Names and Codes (LOINC)
sections, we collected only the following eight medical-
condition related sections as our source for medical-
condition extraction, during the study: [23]
 Boxed Warning sections with the LOINC code of
34066–1
 Precautions sections with the LOINC code of 42232–9
 Warning and Precautions sections with the LOINC
code of 43685–7lected medical conditions and the conditions collected in




Urea stinging ADVERSE REACTION
Urea burning ADVERSE REACTION
…… …… ……
he XML tags of the original label.
Table 2 List of 15 selected drug labels
Rx_Top200 (23) Rx_Other (13)
Drug Name NDC Drug Name NDC
Diovan 0083-4001-01 UREA 42192-101-10
ARICEPT 62856-851-30 GlucaGen HypoKit 0169-7065-15
DORYX 50546-550-01 Tramadol Hydrochloride 54868-4638-6
BENICAR HCT 65597-107-11 Lisinopril 51138-139-30
Copaxone 0088-1153-30 Glyburide 23155-058-10
OTC (16)
Drug Name NDC
Natural Fiber PowderOrange Flavor 53329-102-56
WhiskCare 373 65585-373-04
Degree for Men CleanAntiperspirant and Deodorant 64942-0866-2
UltrasolSunscreenSunscreen Lotion SPF 34 59886-319-11
Topcare Allergy 36800-479-68
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 Contraindications sections with the LOINC code of
34070–3
 Overdosage sections with the LOINC code of
34088–5
 Indications & Usage sections with the LOINC code
of 34067–9
 Adverse reactions sections with the LOINC code of
34084–4Gold standard annotation
Two categories of medical conditions were manually an-
notated: Disease/Disorders (DD) and Sign/Symptoms
(SS). The guidelines for annotation were aligned with
the Strategic Health IT Advanced Research Projects
(SHARPn) Research Focus Area 4: Secondary Use of
EHR Data’s annotations to provide future interoperabil-
ity between our and the SHARPn clinical corpus [24].
All documents were double annotated by two native
English speakers. One annotator had a clinical back-
ground (BSN, RN), and the other annotator had a
Bachelor of Arts degree and extensive experience in
annotating medical documents. The F-measure of inter-
annotator agreement (IAA) is 0.85. Chapman et al. dem-
onstrated that using both clinician and non-clinician
annotators will not bias the annotated corpus, although
non-clinicians need longer training times [25]. Disagree-
ments were discussed and resolved by a third party; in
our case, it was an NLP researcher. Details of the corpus
and the process of gold standard development are thor-
oughly described in a separate paper [26]. The final gold
standard was the result of consensus-seeking adjudica-
tion. Our corpus will be released publicly when the grant
funded period ends (December 2013).Table 1 shows an excerpt of an annotated drug label—
Urea 40 Gel/Lotion. This drug label has two related
LOINC sections – Indication and Adverse Reaction. The
disease of hyperkeratotic lesion and sign/symptoms of
stinging and burning are detected. With these extractions,
the final triples are integrated, in this example as [Urea 40
Gel/Lotion]-[stinging]-[Adverse Reaction], and stored in
the database according to the “[(1) drug name]-[(2) med-
ical condition]-[(3) LOINC section header]” structure.
Descriptive statistics of the corpus
Table 3 shows the basic descriptive statistics of this cor-
pus, including the number of annotated entities in the
gold standard at token and span levels for each drug cat-
egory. Because the original drug labels were in XML for-
mat, a simple parser was applied to extract the plain
texts for these labels. The corpus of plain texts with
eight related sections had 96,824 tokens (1,862 tokens
per document). The OTC drugs have only two sections
– Warning and Indications & Usages. These two sec-
tions are also the most frequent sections in the whole
corpus. There are 8,611 annotated medical conditions in
the corpus (121 for OTC; 2,091 for Rx_Top200; and
1,391 for Rx_Other); the average number of annotated
medication conditions per document is 274.
Rx documents have more medical conditions than the
OTC documents. The average number of medical condi-
tions per document in Rx (128 for Rx_Top200 and 90
for Rx_Other) is 16 times greater than in OTC drugs
(6 for OTC). Although the average of the DD entities
(5 per document) is close to the average of the SS en-
tities (7 per document) in OTC documents, the average
of the DD entities (274 in Rx_Top200 and 293 in
Rx_Other) is more than twice the average of SS entities
(90 in Rx_Top200 and 144 in Rx_Other) in Rx docu-
ments. Approximately one-third of the medical condi-
tions (8,611) are unique (2,953).
Evaluation method
For method development, the gold standard was divided
into experimental and development sets. We held out
7,024 tokens and 74 annotated entities (or two docu-
ments randomly selected from the corpus) as the devel-
opment set for manual error analysis. Although the
number of named entities is large (8,611), they are
distributed only in a smaller number of the documents
(52), which serve as “containers” for the named entities.
On average, the documents contained 166 annotated
gold standard examples. However, some documents
contained as many as 236 and some as few as 8 anno-
tated gold standard examples. Splitting the documents
into 10 subsets—required for 10-fold cross validation—
would have created an uneven distribution of the anno-
tated examples and, while some of the sets would have
Table 3 Descriptive statistics of medical conditions in the annotated drug labels
OTC Rx_Top200 Rx_Other ALL
Token Disease/Disorder (DD) All 83 6,295 3,806 10,184
Unique 46 1,129 737 1,423
Sign/Symptom (SS) All 104 2,072 1,867 4043
Unique 46 525 437 742
Medical Conditions (DD&SS) All 187 8,367 5,673 14,227
Unique 92 2,942 11,74 2,165
Span Disease/Disorder (DD) All 67 1,443 1271 2781
Unique 39 553 470 860
Sign/Symptom (SS) All 54 3,642 2144 5840
Unique 30 1,547 927 2114
Medical Conditions (DD&SS) All 121 5,085 3415 8,611
Unique 69 2,091 1391 2,953
(Total=total number of tokens in that category, all=absolute number, unique = unique number).
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would have included too few. To achieve more evenly
distributed training and testing sets in the cross valid-
ation setting, we chose four-fold cross validation. That
is, the gold standard set was randomly divided into four
sets. Each subset included an average of 23,449 tokens
and 2,134 annotated entities. Each time, the system
trained on three subsets and tested on one subset. The
testing subset is always different from the training sets
to preserve the integrity of the testing, but each of the
four subsets is rotated through as a test subset, while
using the other three subsets for training. The reported
results for the baseline and experimental systems are the
averages of the four-fold cross validation sets. It is im-
portant to note that the sample size of the gold standard
(and the performance of the machine learning algo-
rithm) is based on the number of annotated tokens
(8,611) and not the documents (52).
We measured standard NLP performance statistics,
using precision/positive predictive value (P), recall/sensi-
tivity (R), and F-measure (F), on both token and span
levels [27,28]. P measures the number of true positive
findings in relation to all findings, i.e., P=TP/(TP+FP)
(where TP represents true positives and FP represents
false positives). R measures the number of true positive
findings in relation to all potential findings, i.e., R=TP/
(TP+FN) (FN represents false negatives). F-measure is
the harmonic mean of R and P, i.e., F=(2*P*R)/(P+R)
[29]. The findings are presented for token level measure-
ment (tokens in the documents) and span level measure-
ment (spans or phrases in the documents). We did not
use receiver operating characteristic (ROC) analysis, be-
cause it is not the most appropriate measure for the
sequence-learning problem (such as named entity recog-
nition in textual documents). ROC requires the numberof negative cases to be computed, which is unknown in
the case of named entities, as the entities are sequences
of words [29]. Therefore, we used F-measure for the
evaluation, as is standard.
Since the boundaries for medical conditions are often
ambiguous, various matching criteria have been used on
the span level. As such, we considered exact match, left
match, right match, and partial match, as described by
Tsai [30]. An exact match means the medical condition
within the whole span is the same as the gold standard;
the partial match criteria was also adopted because we
assume that finding pieces of information is better than
finding nothing at all. A left match is defined if the left
boundary of the span matches exactly; a right match is
defined if the right boundary of the span matches
exactly; and a partial match is when any fragment in the
span is correctly detected. Therefore, a left/right/partial
match is helpful for indicating the performance of a sys-
tem as well as for further error analyses. For example, if
the system annotated only the token of “nausea” as sign/
symptom for the sentence, “Side effects may include
nausea and vomiting” (while the gold standard marked
“nausea and vomiting” as a medical condition), then this
extraction is correct on the left boundary detection but
fails at the right boundary and is also considered a par-
tial match.
We tested the statistical significance of the differences
between the results of various system outputs using ap-
proximate randomization, which is not dependent on
the underlying distribution of the data [31].
A Hybrid pipeline
The hybrid pipeline for medical condition mining in
FDA drug labels is called AutoMCExtractor. The first
step is preprocessing; during this, plain texts with related
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cTAKES is executed on these text files to generate fea-
ture sets. The second step’s component uses a super-
vised learning method, CRF, to detect candidate medical
conditions from the text excerpts. The final step’s com-
ponent uses a dictionary-based approach to further im-
prove the detection of medical conditions. Figure 1
depicts the pipeline in a graphical format.
Preprocessing
The preprocessing step converts the input XML re-
sources into plain texts and detects eight medical-
condition-related LOINC sections in the XML files. We
did not remove any stop words, nor did we do any stem-
ming of the medical condition annotation and extrac-
tion; all of the medical conditions are annotated and
extracted as they appeared in the documents. cTAKES is
executed to generate the potential features for the
medical condition identification. Simple linguistic fea-
tures, such as tokens and POS, can be directly extracted
from cTAKES results. The semantic features, such as
SNOMED CD codes and TUIs (Type Unique Identifier),
are also extracted from cTAKES results, but with an ad-
vanced algorithm. Figure 2 shows an example of a
cTAKES output where the terms “cellulitis, malaise, sep-
sis” are linked to the SNOMED CD codes with the asso-
ciated TUI code of “T047”. We used the following three
steps to link “cellulitis” with the TUI code of T047 with
cTAKES results: (1) cellulitis’s begin and end offsets are
discovered by cTAKES as characters 17663 and 17673
and assigned to the ontology concept array ID 356661;
(2) the ontology array’s concept ID (356661) is matched
to the correct array that includes an array element that
has a UIMA_UMLS ID of 356640; and (3) the 356640
UIMA_UMLS ID is then paired with an associated set of
SNOMED CT, UMLS CUI and UMLS TUI codes.
CRF-based medical condition extraction
Selected components of the cTAKES output serve as
partial input for the feature generation of the CRF super-
vised learning algorithm. We use MALLET’s CRF imple-
mentation [31]. Traditional BIO labels are used for the
sequence labelling. That is, the beginning tokens of med-
ical conditions are labelled as MC_B; the tokens withinFigure 1 Automatic Medical Condition Extractor (AutoMCExtractor).medical conditions are labelled as MC_I; and all other
tokens are labelled as O. Different features are gene-
rated, including token features, linguistic features, and
semantic features. Token features indicate the character-
istics of the current token as well as its contexts, includ-
ing the current token itself, the stem of the current
token, the previous two tokens, and the next two tokens.
Linguistic features include the Part-Of-Speech (POS)
tags for the current token and POS tags for a 5-token
window. Semantic features indicate whether the token
belongs to certain thesauri, such as SNOMED CT.
Table 4 lists the complete set of features used in the
CRF algorithm, where the features in bold are utilized
directly from the cTAKES output and the rest of the fea-
tures are generated or modified by custom-developed
processes.
Rule-based post-processing
Based on error analysis of the development set, we
defined post-processing steps involving regular expres-
sions to improve medical condition detection. It is a
dictionary-based approach to complement the super-
vised learning algorithm. If the same medical condition
occurs in the training set, then it will be annotated in
the testing set, even though the CRF system does not
recognize it. For example, “infection” and “photosensitiv-
ity” were considered to be medical conditions in the
training set, although the CRF classifier may have failed
to detect them; however, according to the post-
processing rules, they were still labelled as medical con-
dition during testing. If multiple medical conditions can
be matched, then the maximum coverage rule will be
applied. That is, the rule will only label the longest spans
that match the medical conditions appearing in the
training set. For example, for the phrase of “nausea and
vomiting,” if “nausea,” “vomiting” and “nausea and
vomiting” all exist in the corpus, then only “nausea and
vomiting” are labelled as medical condition.
Experimental settings
We built two rule-based baseline systems and three
CRF-based experimental systems to evaluate our mining
approach. The results of the baseline and experimental
systems were compared in the evaluation phase against
Figure 2 Excerpt of cTAKES Output.




The original form of the current token, the
lowercase form, and the stemmed form of the
current token.
Tokens in the 5-
window size
The previous two tokens and the next two
tokens in their original form.
Bigram of current
token
The current token bigram and the previous token
bigram.
Linguistic features
POS features The Part-Of-Speech (POS) of the tokens in a 5-
token window, including the current token, the
previous two tokens, and the next two tokens.
Initial capital
features
The features indicating whether the tokens
(including the current token, the previous two




The features indicating whether the current token
is digital or alphabetic or mixed.
Capital feature The feature indicating whether the current token
is all capitalized or mixed with capital characters.
Prefix and suffix The prefix and suffix of the current token (first or
last two characters).
Token length The character length of the current token.
Semantic features
CUI The CUI code of the current token from cTAKES
by using dictionary based method.
TUI The TUI code of the current token assigned by
cTAKES, which provides the semantic type
information contained in the UMLS thesaurus.
Note: the features in bold are utilized directly from the cTAKES output; the
rest of the features are generated or modified by
custom-developed processes.
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and tested in a four-fold, cross-validation setting. Table 5
summarizes these five systems.
 Baseline I: a rule-based medical condition extraction
method. This baseline assumes that semantic types
assigned by cTAKES can identify the entities of DD
and SS. The cTAKES TUIs lookup generated the
UMLS TUI codes for the medical condition terms.
These semantic types were selected based on the
SHARPn guidelines to achieve consistency with the
annotation from our gold standard [24]. The SHARPn
guidelines excluded T033 (Finding) from the selection
because it is a noisy semantic type and can
correspond to several different classes such as Signs





ExperSince the TUIs and the entities of DD and SS are
not in a one-to-one mapping, in the subsequent
step, we used the following semantic types as
medical conditions: Congenital Abnormality (with the
TUI code of T019), Acquired Abnormality (with the
TUI code of T020), Injury or Poisoning (with the TUI
code of T037), Pathologic Function (with the TUI code









riment I X X X
riment II X X X X
iment III X X X X





MC_B 0.661 0.575 0.615
MC_I 0.890 0.21 0.338
Overall 0.775 0.391 0.476
Span Exact Match 0.827 0.506 0.628
Baseline II
Token
MC_B 0.804 0.733 0.767
MC_I 0.811 0.473 0.597
Overall 0.808 0.603 0.681
Span Exact Match 0.888 0.698 0.781
Experiment I
Token
MC_B 0.910 0.782 0.841
MC_I 0.936 0.660 0.773
Overall 0.919 0.731 0.814
Span
Exact Match 0.886 0.766 0.822
Left Match 0.915 0.862 0.888
Right Match 0.941 0.877 0.908
Partial Match 0.982 0.849 0.911
Experiment II
Token
MC_B 0.928 0.831 0.877
MC_I 0.942 0.686 0.793
Overall 0.933 0.771 0.844
Span
Exact Match 0.900 0.812 0.854
Left Match 0.931 0.841 0.886
Right Match 0.944 0.852 0.900
Partial Match 0.985 0.889 0.935
Experiment III
Token
MC_B 0.912 0.787 0.845
MC_I 0.936 0.663 0.775
Overall 0.920 0.735 0.817
Span
Exact Match 0.886 0.769 0.824
Left Match 0.917 0.844 0.879
Right Match 0.944 0.861 0.900
Partial Match 0.982 0.852 0.912
Table 7 The statistical significance tests (with p-values <
0.007)
Precision Recall F-measure
Baseline I vs. Baseline II <0.0001 <0.0001 <0.0001
Baseline II vs. Experiment I 0.003 <0.0001 <0.0001
Baseline II vs. Experiment II 0.001 <0.0001 <0.0001
Baseline II vs. Experiment III 0.0018 <0.0001 <0.0001
Experiment I vs. Experiment II 0.039 <0.0001 <0.0001
Experiment I vs. Experiment III 0.147 0.0409 0.0264
Experiment II vs. Experiment III 0.215 <0.0001 <0.0001
Note 1: Statistical significance was tested using approximate randomization
[32].
Note 2: Bonferroni correction was applied because of multiple comparisons
[33].
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code of T048), Cell or Molecular Dysfunction (with the
TUI code of T049), Experimental Model of Disease
(with the TUI code of T50), Signs and Symptoms (with
the TUI code of T184), Anatomical Abnormality (with
the TUI code of T190), and Neoplastic Process (with
the TUI code of T191).
 Baseline II: another rule-based extraction system,
where all terms in the test set were tagged as
medical conditions, if the same term also appeared
in the training set. The pattern matching approach
was performed according to the longest exact match
method. It assumed the system had a dictionary
(generated from the training set) and used this
dictionary to detect medical conditions in the testing
set. This is considered to be a pattern matching
approach.
 Experimental I: an implementation of the
AutoMCExtractor system. The system uses
MALLET CRF for the supervised sequence learning
with the basic feature set of token features and
linguistic features, as described in Table 4. These
features were used in our previous project for
medication name detection in clinical notes and
showed excellent performance.
 Experimental II: an implementation of our
AutoMCExtractor system. The system uses
MALLET CRF for the supervised sequence learning
with the same token and linguistic features as in
Experimental I but added TUIs as features, as
described in Table 4.
 Experimental III: an implementation of our
AutoMCExtractor system. The system uses
MALLET CRF with token and linguistic features but
added CUIs, as described in Table 4. TUIs are not
included as a feature in this experiment.
Results
Evaluation results on both token and span levels are
shown in Table 6. Since the two baseline systems use
rule-based methods, only exact match results are
reported on the span level. For baseline systems, Base-
line II performs better (0.888, 0.698, and 0.781 for P, R,
and F-measure respectively) than Baseline I (0.827,
0.506, and 0.628) on the token level evaluation.
For experimental systems, Experiment II has the
highest performance on both the token (0.933, 0.771,
and 0.844) and span (0.90, 0.812, and 0.854) levels (exact
match). Experiment III shows the second best perform-
ance (0.921, 0.734, and 0.817 on the token level; and
0.886, 0.769, and 0.824 for the span level, exact match).
Experiment I has P, R, and F-measure of 0.919, 0.731,
and 0.814, respectively, on the token level; and 0.886,
0.766, and 0.822, respectively, at the exact span match
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cally significantly better than the two baseline systems
(p<0.05) on the span level as tested by approximate
randomization, as shown in Table 7.
In the best-performing system, Experiment II, the par-
tial match performance scores (0.985, 0.889, and 0.935)
are higher than the right match (0.944, 0.852, and 0.903)
scores and left match (0.931, 0.840, and 0.891). All of
these matches have higher scores than the exact match.
The same trend also exists in the other experimental
systems, Experiment I and Experiment III.
The corresponding p-values for the span-level, statis-
tical-significance tests are shown in Table 7. Due to the
number of different tests conducted, we applied a
Bonferroni correction to account for the increased possi-
bility of Type I error. Thus, to adjust for 7 different
significance tests with multiple variables that may not be
independent, the performance was considered statisti-
cally significant at p-values lower than 0.007, i.e., 0.05/7
[33]. Baseline I versus Baseline II, Baseline II versus Ex-
periment I, Baseline II versus Experiment II, Baseline II
versus Experiment III, and Experiment I versus Experi-
ment II have p-value lower than 0.007 among the preci-
sion statistical significance tests. All the recall and F-
measure comparisons are found to be statistically signifi-
cant, except in the comparison of Experiment I and Ex-
periment III.
Discussion
We reported the average of four-fold cross validation
performance statistics. As shown in Tables 6 and 7,
Baseline II is statistically significantly better than Base-
line I in precision, recall and F-measure, according to
the approximate randomization test. Therefore, we can
conclude that the dictionary-based pattern matching ap-
proach (Baseline II), i.e., tagging all terms by longest
exact match in the test set if the matching terms were
also tagged in the training set, is better than the TUI-
based extraction approach (Baseline I).
The experimental systems are statistically significantly
better than the baseline systems. That means that our
system, based on the CRF method with both linguistic
and dictionary features, achieves better performance
than either the solely dictionary-based or TUI-based ex-
traction systems. The system of Experiment II is statisti-
cally significantly better than the Experiment I system
(for recall and F-measure), which indicates that the TUI
feature helps in identifying more medical conditions
with higher accuracy. Although Experiment III has sta-
tistically significantly better performance than Experi-
ment II on recall and F-measure, it is not significantly
improved with respect to precision. This means that the
CUI feature is not useful in finding more medical
concepts.The error analysis on the development set showed
that the false positives were mainly due to boundary-
detection errors (five out of seven). For instance, in the
phrase “generalized rash”, both “generalized” and “rash”
were tagged by the system, while only “rash” was tagged
in the gold standard as a medical condition (“general-
ized” is considered an attribute in the gold standard cor-
pus). False negatives were mostly single-word concepts
that were missed by the system (three out of four). For
example, “insulinoma” was not detected by our system.
In the three experimental systems, the performance of
partial match is better than right match, right match is
better than left match, and left match is better than
exact match in P, R, and F (i.e., partial match > right
match > left match > exact match). Exact match is a
stricter measurement than partial match—it requires
that both the left boundary and the right boundary be
correct. For example, if the gold standard annotates
“generalized rash” as medical condition (while the sys-
tem only identifies “rash”), then it is a partial match and
right match, but neither a left match nor exact match.
This can diminish both precision and recall for the left
match and exact match evaluation. The F-measure for
the partial match is greater than 0.91, which demon-
strates that the system can detect the medical conditions
very well, at least partially. However, the F-measure for
exact match is only 0.82, which means that the system
fails at boundary detections (especially the left boundary
detection), since the performance of right match is bet-
ter than left match. In error analysis, non-matches for
the left boundary were seen with modifiers in front of
the medical concepts, such as “inflammatory lesions.”
Precision of token-level evaluation is better than the
span-level exact match, but the span-level exact match is
better than token-level exact match for recall and F-
measure for all three experimental systems. Therefore,
in this hybrid system, recall has a greater effect on over-
all system performance (F-measure) than precision.
One of the limitations of our current study is that we
did not take into account dis-continuous entities, such
as “muscle…weakness” in “muscle tenderness or weak-
ness”. Discontinuous entities are hard to represent ac-
curately in the input format of a standard CRF sequence
labelling system, i.e., BIO format. They represent about
five percent of all annotated entities. This limitation also
explains the performance difference between detecting
beginning tokens of medication conditions (i.e., MC_B)
and left match. In the continuous and non-overlapping
named entity detection, these two scores should be
exactly the same. However, in an overlapping case, we
count only once for the token level, but multiple times
for the span-level left match. For example, both “muscle
tenderness” and “muscle…weakness” in “muscle tender-
ness or weakness” are annotated in the gold standard.
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(i.e., “muscle”), while span-level left match is counted as
two, since there are two medical conditions.
The current system performance is good (the overall
F-measure is 0.89 for exact match). This is especially
true compared with the inter-annotator agreement
(F-measure of 0.85). In essence, the system recognizes
the medical conditions as well as the human annotators
and behaves as a third human annotator. However, the
recall is still relatively low (0.889 for partial match of Ex-
periment III). If we exclude the discontinuous named en-
tities (about 5%), the recall is around 0.94. In our future
work, we will further investigate methods for improving
the coverage for medical conditions. Moreover, we will ad-
dress discontinuous medical condition detection, which
will most likely be identified through post-processing rules
or an ensemble machine learning approach.
In the next phase of development, we will test the full
pipeline on a selected set of drugs to directly monitor
ADRs, which we collect from FDA labels in the EHR.
However, that system will require development of fur-
ther components of the ADR monitoring pipeline (in-
cluding a component that extracts relevant data from
the EHR). We anticipate that especially in the beginning,
the intelligent database system of which the NLP system
described here will be a component will need human
supervision, but we are also planning to develop add-
itional components for the data collection from diverse
information sources (e.g. journal texts/abstracts and the
AERS data set) and use statistical cross-referencing to
increase the reliability of the collected and stored “drug/
medical condition/LOINC header” triples.
Conclusions
This study offers three main contributions to the litera-
ture. First, we demonstrated that medical conditions could
be extracted from FDA drug labels, which is a ubiquitous
source of information, with high performance using scal-
able NLP methods. Second, incorporating the open source
cTAKES clinical NLP system into our pipeline, we ex-
plored the features used for detecting medical conditions
in sequence learning. To our knowledge, this is the first
study that makes comprehensive use of linguistic and se-
mantic processing from cTAKES outside of the domain of
clinical notes and in combination with de novo generated
features that are incorporated into feature vectors for a
machine learning algorithm. Although many sequence
learning tasks, especially named entity recognition, use
CRF algorithms, the feature details are rarely discussed in
the literature and complete evaluations are not available
for clinical notes. Third, the AutoMCExtractor serves as a
proof of the concept that an intelligent database of drugs
and corresponding medical conditions can be built. Al-
though collecting “drug/medical condition/LOINC” triplesis only the first step in developing an intelligent ADR de-
tection database, it is nonetheless an important step to-
ward large-scale automated ADR detection.
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